In this episode of RhAPPcast, host Amanda Mixon, President of RhAPP, is joined by pediatric rheumatology specialist and RhAPP board member Brandon Ko to spotlight hypophosphatasia (HPP) in children—an underrecognized inherited metabolic bone disorder that is frequently missed in clinical practice. The conversation reviews perinatal, infantile, and childhood-onset HPP, highlights subtle early warning signs like failure to thrive, delayed milestones, craniosynostosis, bone pain, recurrent fractures, and premature loss of primary teeth with intact roots, and explains why persistently low alkaline phosphatase (ALP) is a key diagnostic red flag. Designed for rheumatology APPs and primary care clinicians, this episode offers practical steps to improve recognition, differentiate HPP from conditions like JIA and pain amplification syndromes, and support earlier evaluation and referral for appropriate testing.

In this episode of RhAPPcast, host Amanda Mixon, President of RhAPP, is joined by rheumatology PA Audrey Gibson for an in-depth discussion on IL-23 inhibitors and what differentiates them in real-world rheumatology practice. The conversation reviews the IL-23/Th17 pathway, current approved IL-23 inhibitors for psoriatic arthritis, and key considerations around efficacy, safety, durability, and patient selection, including comorbid psoriasis and inflammatory bowel disease. Designed for rheumatology APPs, this episode also explores practical expectations for treatment response, emerging clinical trial data, and how IL-23 inhibitors fit into a domain-based approach to managing psoriatic disease.

In this FAQ, Brandon Ko, APRN, a pediatric rheumatology nurse practitioner and RhAPP Pediatric Chair, provides a practical overview of hypophosphatasia (HPP) across the lifespan and explains why this rare inherited metabolic bone disorder is often missed in clinical practice. The discussion reviews pediatric and adult presentations of HPP, including subtle skeletal symptoms, premature tooth loss with intact roots, stress fractures, osteomalacia, and early-onset pseudogout, and highlights persistently low alkaline phosphatase as a key diagnostic red flag. Designed for APPs and clinicians, this concise video outlines when to suspect HPP, how to begin the evaluation, and why early recognition is critical in both pediatric and adult rheumatology settings.